Corvus Pharmaceuticals Inc — Quarterly Financial Statistics (NASDAQ:CRVS) | MetaTrader

Open full chart

Financials

Overview Finanzbericht Statistics Dividends

Quarterly Annual

Cash from operating activities 6.32 M8.46 M8.26 M5.78 M-9.57 M 12.94 M Cash from investing activities 3.89 M6.08 M4.24 M11.81 M2.62 M 24.76 M Cash from financing activities 335 K0279 K35.77 M360 K — Free cash flow 6.32 M8.46 M8.23 M5.66 M-9.57 M 12.79 M

Nachrichten

Corvus Pharmaceuticals, Inc. (CRVS) Discusses Phase 1 Clinical Trial Results of Soquelitinib in Atopic Dermatitis with Focus on Cohort 4 - Slideshow (NASDAQ:CRVS) 2026-01-27

Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why

Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know

Wall Street Analysts Think Corvus (CRVS) Could Surge 25.29%: Read This Before Placing a Bet

Intel, Oracle among market cap stock movers on Monday

Revolution Medicines, Erasca And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Ambitions Enterprise Mgmt (NASDAQ:AHMA), Argo Blockchain (NASDAQ:ARBK)

Apple, Microsoft, Meta To Report Results; Fed’s Interest Rate Decision In Focus

Corvus Pharmaceuticals schließt aufgestockte Kapitalerhöhung mit 201,2 Mio. US-Dollar ab

Corvus Pharmaceuticals raises $201.2 million in upsized public offering

Cantor Fitzgerald bestätigt ’Overweight’-Rating für Corvus Pharmaceuticals nach starken Studiendaten

Cantor Fitzgerald reiterates Overweight rating on Corvus Pharmaceuticals stock

Jefferies hebt Kursziel für Corvus Pharmaceuticals nach starken Alzheimer-Daten auf 42 US-Dollar an/n